^
CD20 expression + PAX5 expression + BCL2 expression
Marginal Zone Lymphoma
rituximab
Sensitive: C4 – Case Studies
Am Surg - 3 weeks
No biomarker
Marginal Zone Lymphoma
zanubrutinib
Sensitive: A1 - Approval
No biomarker
Marginal Zone Lymphoma
umbralisib
Sensitive: A1 - Approval
No biomarker
Marginal Zone Lymphoma
ibrutinib
Sensitive: A1 - Approval
No biomarker
Marginal Zone Lymphoma
R-CVP
Sensitive: A2 - Guideline
No biomarker
Marginal Zone Lymphoma
R-CHOP
Sensitive: A2 - Guideline
No biomarker
Marginal Zone Lymphoma
rituximab + lenalidomide
Sensitive: A2 - Guideline
No biomarker
Marginal Zone Lymphoma
rituximab
Sensitive: A2 - Guideline
No biomarker
Marginal Zone Lymphoma
axicabtagene ciloleucel
Sensitive: A2 - Guideline
No biomarker
Marginal Zone Lymphoma
obinutuzumab
Sensitive: A2 - Guideline
No biomarker
Marginal Zone Lymphoma
idelalisib
Sensitive: A2 - Guideline
No biomarker
Marginal Zone Lymphoma
duvelisib
Sensitive: A2 - Guideline
No biomarker
Marginal Zone Lymphoma
copanlisib
Sensitive: A2 - Guideline
No biomarker
Marginal Zone Lymphoma
cyclophosphamide oral
Sensitive: A2 - Guideline
No biomarker
Marginal Zone Lymphoma
chlorambucil
Sensitive: A2 - Guideline
No biomarker
Marginal Zone Lymphoma
ibritumomab tiuxetan
Sensitive: A2 - Guideline
No biomarker
Marginal Zone Lymphoma
lenalidomide + obinutuzumab
Sensitive: A2 - Guideline
No biomarker
Marginal Zone Lymphoma
G-CHOP
Sensitive: A2 - Guideline
No biomarker
Marginal Zone Lymphoma
lisocabtagene maraleucel
Sensitive: A2 - Guideline
No biomarker
Marginal Zone Lymphoma
tisagenlecleucel-T
Sensitive: A2 - Guideline
No biomarker
Marginal Zone Lymphoma
O-CVP
Sensitive: A2 - Guideline
No biomarker
Marginal Zone Lymphoma
INCB50465
Sensitive: B - Late Trials
Incyte Press Release - 4 weeks
MYD88 mutation
Marginal Zone Lymphoma
ibrutinib
Sensitive: C3 – Early Trials
CARD11 mutation
Marginal Zone Lymphoma
ibrutinib
Resistant: C3 – Early Trials
KMT2D mutation
Marginal Zone Lymphoma
ibrutinib
Resistant: C3 – Early Trials
MYD88 L265P
Marginal Zone Lymphoma
ibrutinib
Sensitive: C3 – Early Trials
TNFAIP3 mutation
Marginal Zone Lymphoma
ibrutinib
Sensitive: C3 – Early Trials
CD5 positive
Marginal Zone Lymphoma
rituximab
Resistant: C3 – Early Trials
LDH elevation
Marginal Zone Lymphoma
ViPOR
Sensitive: C3 – Early Trials
TP53 mutation + MET amplification + PD-L1 overexpression
Marginal Zone Lymphoma
sintilimab
Sensitive: C4 – Case Studies
NOTCH2 mutation + NCOA4 mutation + PTEN mutation + EPHA3 mutation + KMT2D mutation
Marginal Zone Lymphoma
rituximab
Sensitive: C4 – Case Studies
BIRC3-MALT1 fusion
Marginal Zone Lymphoma
R-CHOP
Sensitive: C4 – Case Studies